[Neoadjuvant systemic therapy in breast cancer].

Area of Science:

• Oncology
• Medical Treatment

Context:

• Neoadjuvant systemic therapy is a viable treatment option for symptomatic, locoregional stage breast cancers.
• Tumor characteristics guide the selection of chemotherapy or hormone therapy.

Purpose:

• To evaluate the efficacy and impact of neoadjuvant systemic therapy in breast cancer treatment.
• To highlight the importance of detailed patient and tumor assessment before initiating therapy.

Summary:

• Preoperative chemotherapy or hormone therapy leads to tumor regression in most cases, facilitating breast-conserving surgery.
• Pathological tumor characterization is crucial for selecting effective treatments like taxane/anthracycline-based polychemotherapy or aromatase inhibitors.
• Trastuzumab combined with chemotherapy shows promising response rates. Post-therapy imaging and surgery are followed by radiotherapy.

Impact:

• Neoadjuvant therapy's long-term effects are equivalent to adjuvant therapy, with observed in vivo efficiency correlating with prognosis.
• This approach avoids surgical delays due to potential adverse effects and enhances the feasibility of breast-conserving surgery.